Company Filing History:
1 out of 9 
1 out of 117 
Years Active: 2020
Title: Adrian Bracken: Innovator in Cancer Recurrence Prediction
Introduction
Adrian Bracken is a notable inventor based in Dublin, Ireland. He has made significant contributions to the field of cancer research, particularly in predicting the risk of cancer recurrence. His innovative approach has the potential to impact patient care and treatment strategies.
Latest Patents
Adrian Bracken holds a patent for a method of predicting the risk of recurrence of cancer. This method involves assaying a cancer sample from an individual for positive expression of at least two genes or proteins. The genes selected include FOXM1, UHRF1, PTTG1, E2F1, MYBL2, HMGB2, ATAD2, E2F8, ZNF367, and TCF19. Positive expression of these genes correlates with an increased risk of cancer recurrence compared to individuals who do not exhibit such expression. This patent represents a significant advancement in personalized medicine.
Career Highlights
Throughout his career, Adrian has worked with prestigious institutions, including Trinity College Dublin and University College Dublin. His work in these academic environments has allowed him to collaborate with leading researchers and contribute to groundbreaking studies in cancer biology.
Collaborations
Adrian has collaborated with notable colleagues such as Fiona Lanigan and William Gallagher. Their combined expertise has fostered a productive research environment, leading to advancements in understanding cancer recurrence.
Conclusion
Adrian Bracken's innovative work in predicting cancer recurrence exemplifies the importance of research in improving patient outcomes. His contributions to the field are invaluable and highlight the potential of genetic analysis in cancer treatment.